DUBLIN, Nov 18 (Reuters) - Ireland's Elan wonapproval from shareholders on Monday to complete the sale of thecompany to U.S. drugmaker Perrigo, clearing the way forthe deal to be completed by the end of the year.
Perrigo agreed to buy the Dublin-based group for $8.6billion in July in a deal that will hand it tax savings frombeing domiciled in Ireland and royalties from blockbustermultiple sclerosis treatment Tysabri.
The deal ended a bitter takeover battle in which Elanrejected three lower bids from U.S. investment firm RoyaltyPharma.
- Health Care Industry
- Mergers, Acquisitions & Takeovers